Advertisement
Advertisement
Trending on CancerNetwork
1
123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis
2
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
3
TIP126 TroFuse-011: A Phase 3, Randomized, Open-Label Study of Sacituzumab Tirumotecan With or Without Pembrolizumab vs Treatment of Physician’s Choice for Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer With PD-L1 Combined Positive Score <10
4
122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes
5